These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32476517)

  • 1. Optimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation.
    Robinson DH; Hughes CFM; Grigg A
    Leuk Lymphoma; 2020 Oct; 61(10):2448-2452. PubMed ID: 32476517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft.
    McClelland J; Wong E; Grigg A
    Leuk Lymphoma; 2023 Feb; 64(2):440-444. PubMed ID: 36368718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
    Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
    Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
    Jeong W; Haywood P; Shanmuganathan N; Lindsay J; Urbancic K; Ananda-Rajah MR; Chen SC; Bajel A; Ritchie D; Grigg A; Seymour JF; Peleg AY; Kong DC; Slavin MA
    J Antimicrob Chemother; 2016 Dec; 71(12):3540-3547. PubMed ID: 27521358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.
    Heinz WJ; Einsele H; Helle-Beyersdorf A; Zirkel J; Grau A; Schirmer D; Lenker U; Klinker H
    Transpl Infect Dis; 2013 Oct; 15(5):449-56. PubMed ID: 23890126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
    Winston DJ; Bartoni K; Territo MC; Schiller GJ
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation.
    Collins J; Shea K; Parsad S; Plach K; Lee P
    J Oncol Pharm Pract; 2020 Jan; 26(1):5-12. PubMed ID: 30854922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
    Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
    Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.
    Kubiak DW; Koo S; Hammond SP; Armand P; Baden LR; Antin JH; Marty FM
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1462-5. PubMed ID: 22564264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
    N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Heinz WJ; Cabanillas Stanchi KM; Klinker H; Blume O; Feucht J; Hartmann U; Feuchtinger T; Lang P; Handgretinger R; Döring M
    Med Mycol; 2016 Feb; 54(2):128-37. PubMed ID: 26483433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
    Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
    Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Grau S; Cámara R; Jurado M; Sanz J; Aragón B; Gozalbo I
    Eur J Health Econ; 2018 May; 19(4):627-636. PubMed ID: 28569350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients.
    Peña-Lorenzo D; Rebollo N; Sánchez-Hernández JG; Zarzuelo-Castañeda A; Vázquez-López L; Otero MJ; Pérez-Blanco JS
    Eur J Pharm Sci; 2022 Jan; 168():106049. PubMed ID: 34699939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.